Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models

Títulos similares

• Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma
  por: Annamaria Brioli, et al.
  Publicado: (2014-11-01)
• Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents
  por: Paola Tacchetti, et al.
  Publicado: (2017-03-01)
• Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma
  por: Flavia Bigi, et al.
  Publicado: (2024-04-01)
• Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models
  por: Enrica Borsi, et al.
  Publicado: (2018-12-01)
• Front-line treatment of multiple myeloma
  por: Michele Cavo, et al.
  Publicado: (2019-06-01)